Sustainability | July 03, 2022
Pfizer to achieve net-zero standard by 2040
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Pfizer aims to achieve net-zero targets ten years earlier than the expectations of the Net-Zero Standard
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Pfizer to commercialize NURTEC ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
The facility is among 12 centres established worldwide, and the first in Asia
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
Subscribe To Our Newsletter & Stay Updated
